Merck: Q1 EPS reaches $1.70

(CercleFinance.com) - Global sales from continuing operations reached 15.
9 billion dollars in Q1 2022, up 50% y-o-y.

Sales of its blockbuster drug KEYTRUDA increased by 23% to 4.8 billion dollars. Excluding FX factors, sales increased 27%.

GAAP EPS from continuing operations reached 1.70 dollar in Q1 2022, while non-GAAP EPS was 2.14 dollars.

The company is targeting FY 2022 global sales of 56.9 to 58.1billion dollars, up between 17% and 19%, along with FY 2022 GAAP EPS of 5.90 dollars and 6.02 dollars and non-GAAP EPS of 7.24 to 7.36 dollars


Copyright (c) 2022 CercleFinance.com. All rights reserved.